Quest Diagnostics

ExamOne
New Jersey
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Quest Diagnostics scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Quest Diagnostics increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Quest Diagnostics forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Quest Diagnostics supports the LGBT movement and is a corporate partner of the National LGBT Chamber of Commerce. For these reasons, Quest Diagnostics receives a High Risk rating.

Shareholder Proposals

Expand Summary

Date
ESG Category
Proponent
Summary of ResolutionMgmt RecTotal Vote % in Favor
5/17/23EnvironmentalJohn CheveddenStockholder proposal regarding a report on the Company's greenhouse gas emissionsAgainst47.68%
Generate Reports
Clear
Toast